[HTML][HTML] Safety of aflibercept in metastatic colorectal cancer: a literature review and expert perspective on clinical and real-world data
K Muro, T Salinardi, AR Singh, T Macarulla - Cancers, 2020 - mdpi.com
Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden
globally and an increasing challenge in Asian countries. Treatment options include …
globally and an increasing challenge in Asian countries. Treatment options include …
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program
M Salgado Fernandez, MT Perez Hoyos… - Expert Opinion on …, 2015 - Taylor & Francis
Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
Aflibercept: a review in metastatic colorectal cancer
YY Syed, K McKeage - Drugs, 2015 - Springer
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer
DK Lau, J Mencel, I Chau - Expert Opinion on Drug Safety, 2022 - Taylor & Francis
Introduction Anti-angiogenic drugs are an efficacious class of therapy in the treatment of
patients with metastatic colorectal cancer (mCRC). Aflibercept, a vascular endothelial growth …
patients with metastatic colorectal cancer (mCRC). Aflibercept, a vascular endothelial growth …
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
J Feliu, I Díez de Corcuera, JL Manzano… - Clinical and …, 2017 - Springer
Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
[HTML][HTML] Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the global aflibercept safety and health-related quality-of …
RP Riechelmann, V Srimuninnimit, R Bordonaro… - Clinical colorectal …, 2019 - Elsevier
Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
Efficacy and safety of aflibercept in combination with chemotherapy beyond second-line therapy in metastatic colorectal carcinoma Patients: An AGEO multicenter …
M Auvray, D Tougeron, E Auclin, V Moulin, P Artru… - Clinical colorectal …, 2020 - Elsevier
Background Although no data have been reported beyond second-line therapy, aflibercept
is approved in this setting in many countries. We conducted a multicenter study to analyze …
is approved in this setting in many countries. We conducted a multicenter study to analyze …
[HTML][HTML] Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: a single-institution real-life experience
D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - Cancers, 2021 - mdpi.com
Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled …
A Thakur, MR Chorawala, RS Patel - Critical Reviews in Oncology …, 2023 - Elsevier
Background and objective Aflibercept; a decoy receptor for vascular endothelial growth
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …
[HTML][HTML] Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
P Ge, N Wan, X Han, X Wang, J Zhang… - Frontiers in …, 2022 - frontiersin.org
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …